Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 58Thoracic 7Other solid neoplasm 3Gastrointestinal 3Gynecologic 2Genitourinary 2CNS 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1

Conditions

Myelodysplastic Syndromes 425Leukemia, Myeloid, Acute 351Leukemia 240Leukemia, Myelogenous, Chronic, BCR-ABL Positive 232Precursor Cell Lymphoblastic Leukemia-Lymphoma 211Myeloproliferative Disorders 161Lymphoma, Non-Hodgkin 156Hodgkin Disease 135Primary Myelofibrosis 129Leukemia, Lymphocytic, Chronic, B-Cell 129Multiple Myeloma 126Leukemia, Myelomonocytic, Chronic 118Lymphoma 106Leukemia, Myeloid, Chronic-Phase 78Lymphoma, Mantle-Cell 76Lymphoma, Follicular 71Congenital Abnormalities 69Blast Crisis 69Lymphoma, Large B-Cell, Diffuse 67Leukemia, Myeloid, Accelerated Phase 66Polycythemia Vera 64Lymphoma, B-Cell, Marginal Zone 64Burkitt Lymphoma 63Hematologic Neoplasms 53Anemia, Refractory, with Excess of Blasts 52Lymphoma, Large-Cell, Immunoblastic 51Neoplasms, Plasma Cell 47Myelodysplastic-Myeloproliferative Diseases 44Thrombocythemia, Essential 40Recurrence 40

Interventions

AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × Myeloid × Clear all
NCT02743611 2023-10-05

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Bellicum Pharmaceuticals

Phase 1/2 Terminated
4 enrolled 9 charts
DermatologicMyeloidOther hematologic neoplasm

Uveal Melanoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡